CTLA4 and neoplasm: Though not significant, a minor increase in expression of PD-1 and CTLA-4 could be noted, perhaps suggesting an increase in tumor-specific effector T cells and a window for combination therapy with immune checkpoint inhibitors targeting CTLA-4 and/or PD-1 [29].